• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 050 Date of Recognition 09/17/2018 
FR Recognition Number 7-217
Standard
CLSI M60 1st Edition
Performance Standards for Antifungal Susceptibility Testing of Yeasts
Scope/Abstract
This document includes updated minimal inhibitory concentration, zone diameter, and quality control tables for the Clinical and Laboratory Standards Institute antifungal susceptibility testing documents M27 and M44.
Extent of Recognition
Complete standard
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.

Interpretive criteria and quality control parameters when different from that in FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria: Antifungal Susceptibility Test Interpretive Criteria. See relevant guidance below for information on interpretive criteria.
Public Law, CFR Citation(s) and Procode(s)
Regulation Number Device Name Device Class Product Code
§866.1700 Culture Media, Antifungal, Susceptibility Test Class 2 MJE
§866.1640 Susceptibility Test Plate, Antifungal Class 2 NGZ
§866.1620 Discs, Elution Class 2 LTX
§866.1620 Susceptibility Test Discs, Antimicrobial Class 2 JTN
Relevant FDA Guidance and/or Supportive Publications
FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria: Antifungal Susceptibility Test Interpretive Criteria https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm575166.htm
FDA Technical Contacts
 Ribhi Shawar
  FDA/OMPT/CDRH/OIR/DMD/BAC1/
  301-796-6698
  ribhi.shawar@fda.hhs.gov
 Jeffrey Brocious
  FDA/OMPT/CDRH/OIR/DMD
  240-402-3797
  jeffrey.brocious@fda.hhs.gov
Standards Development Organization
CLSI Clinical Laboratory Standards Institute https://clsi.org/
FDA Specialty Task Group (STG)
InVitro Diagnostics
-
-